Last updated: September 9, 2026
Raptiva, the brand name for efalizumab, had a short commercial life in psoriasis. Genentech launched it in the United States in 2003 as a first-in-class anti-CD11a monoclonal antibody for adults with chronic moderate-to-severe plaque psoriasis. The product never reached blockbuster scale. Safety signals, including progressive multifocal leukoencephalopathy (PML), led to voluntary U.S. withdrawal in 2009 and global discontinuation. Raptiva has no active commercial market, no current FDA exclusivity, and no meaningful generic or biosimilar entry opportunity.
Its financial trajectory followed four stages: launch and early adoption, competition from newer biologics, safety-driven contraction, and permanent withdrawal.
What was Raptiva and how did efalizumab work?
Raptiva contained efalizumab, a recombinant humanized monoclonal antibody that bound CD11a, the alpha subunit of leukocyte function-associated antigen-1 (LFA-1). By blocking LFA-1 interactions, efalizumab reduced T-cell activation, migration, and adhesion involved in psoriasis.
The product was administered subcutaneously. The FDA approved an initial 0.7 mg/kg conditioning dose followed by weekly 1 mg/kg maintenance dosing for adults with chronic moderate-to-severe plaque psoriasis who were candidates for systemic therapy or phototherapy.[1]
| Attribute |
Raptiva |
| Active ingredient |
Efalizumab |
| Manufacturer at U.S. launch |
Genentech |
| Therapeutic area |
Chronic moderate-to-severe plaque psoriasis |
| Mechanism |
CD11a/LFA-1 inhibition |
| Dosage form |
Subcutaneous injection |
| U.S. approval |
October 2003 |
| U.S. withdrawal |
June 2009 |
| Principal safety issue |
PML and serious infections |
| Current commercial status |
Discontinued |
Raptiva was a targeted biologic, but its mechanism did not produce a durable competitive advantage once tumor necrosis factor inhibitors and newer psoriasis biologics became established.
When did Raptiva lose exclusivity and commercial protection?
Raptiva lost practical market exclusivity through safety withdrawal rather than through ordinary patent expiry or generic competition. The product was removed from the market before patent expiration became the primary commercial issue.
The key timeline was:
| Date |
Event |
| October 2003 |
FDA approved Raptiva for adult plaque psoriasis |
| 2008 |
FDA added stronger warnings and required enhanced safety communication after serious infections and other adverse events |
| February 2009 |
FDA and Genentech reported three confirmed PML cases in Raptiva-treated patients |
| April 2009 |
Genentech announced voluntary withdrawal from the U.S. market |
| June 2009 |
U.S. commercial withdrawal was completed |
| June 2009 |
European regulators recommended suspension and withdrawal |
| 2010 onward |
Raptiva remained discontinued in major regulated markets |
The FDA stated that the risk-benefit profile had become unfavorable because of PML, a rare and often fatal brain infection associated with immune dysfunction.[2] The European Medicines Agency recommended suspension of marketing authorization after reviewing PML cases and other serious adverse events.[3]
What was Raptiva’s financial trajectory?
Raptiva generated revenue but did not become a major contributor to Genentech’s financial profile. Public company disclosures generally presented the product as a smaller contributor relative to Avastin, Herceptin, Rituxan, Lucentis, and Tarceva.
The commercial trajectory can be divided into four periods:
Launch period: 2003 to 2005
Raptiva entered a psoriasis market with substantial unmet need, but uptake was constrained by weekly injections, immunosuppression concerns, a complex prescribing profile, and competition from established systemic therapies.
The product’s early positioning depended on patients who required biologic treatment but were not adequately managed with conventional systemic therapy or phototherapy. Its target population was clinically significant but narrower than the broader psoriasis market.
Competitive pressure: 2006 to 2008
Raptiva faced direct and indirect pressure from:
- Enbrel, marketed by Amgen and Wyeth, for plaque psoriasis;
- Remicade, marketed by Centocor and Schering-Plough;
- Humira, marketed by Abbott;
- Stelara, approved in 2009 and based on a different interleukin pathway;
- Traditional systemic treatments, including methotrexate and cyclosporine;
- Phototherapy and topical regimens.
TNF inhibitors had larger prescriber familiarity and broader inflammatory-disease franchises. Raptiva’s narrower indication and safety monitoring burden limited its ability to expand beyond dermatology.
Safety contraction: 2008 to 2009
The FDA added a boxed warning in 2008 for serious infections, malignancy, thrombocytopenia, hemolytic anemia, and other risks. Raptiva also carried warnings regarding the potential for psoriasis rebound after treatment discontinuation.[1]
The PML cases in early 2009 caused the commercial collapse. Prescribers had to weigh a psoriasis therapy against a rare but fatal neurological adverse event. The resulting loss of confidence made continued commercial investment impractical.
Post-withdrawal period
After withdrawal, Raptiva had no continuing product revenue base. Genentech and Roche did not have a viable path to relaunch the product because the safety issue affected the core mechanism and risk-benefit profile rather than a correctable manufacturing defect or labeling limitation.
No successor product based on efalizumab was commercialized.
How did Raptiva compare with competing psoriasis biologics?
Raptiva’s competitive position deteriorated because its clinical differentiation was limited while its safety burden increased.
| Product |
Target |
Initial psoriasis role |
Commercial outcome relative to Raptiva |
| Raptiva |
CD11a/LFA-1 |
Systemic biologic for plaque psoriasis |
Withdrawn in 2009 after PML |
| Enbrel |
TNF-alpha |
Broad psoriasis and rheumatology franchise |
Sustained large commercial franchise |
| Remicade |
TNF-alpha |
Infused biologic for psoriasis and autoimmune diseases |
Benefited from multi-indication use |
| Humira |
TNF-alpha |
Psoriasis and multiple immune-mediated diseases |
Expanded through broad indications |
| Stelara |
IL-12/23 |
Psoriasis and later inflammatory diseases |
Stronger durability and expanded label |
| Cosentyx |
IL-17A |
Psoriasis and related diseases |
Later-generation efficacy competitor |
| Tremfya |
IL-23 |
Plaque psoriasis |
Modern class competitor |
Raptiva was disadvantaged by its weekly dosing, limited indication set, and immunological safety profile. Competitors also had greater value from multi-indication prescribing, which supported larger sales forces and payer contracts.
What patents protected Raptiva?
Raptiva was protected by biologic product, antibody, manufacturing, and use-related intellectual property rather than by a simple small-molecule composition-of-matter patent.
The commercially relevant patent categories included:
- Humanized anti-CD11a antibodies.
- Antibody binding to the CD11a component of LFA-1.
- Methods for treating psoriasis and immune-mediated disease.
- Recombinant antibody production and purification.
- Pharmaceutical compositions and injectable formulations.
The practical patent value was limited by the product’s withdrawal. Even if patent rights remained in force after 2009, they no longer created meaningful market leverage because the reference product was unavailable for ordinary substitution.
The historical FDA Orange Book is less consequential for Raptiva than it is for small-molecule products. Biologics approved under the pre-Biologics Price Competition and Innovation Act framework were not managed through the modern Orange Book patent-certification model. Raptiva therefore did not generate the type of active Paragraph IV litigation commonly associated with branded oral drugs.
Were there Paragraph IV challenges or biosimilar threats?
No commercially material Paragraph IV challenge drove Raptiva’s exit. The product’s withdrawal preceded the modern U.S. biosimilar market and removed the economic incentive to pursue a follow-on version.
Raptiva also has no meaningful present biosimilar threat. A biosimilar applicant would face several commercial barriers:
- The reference product is no longer actively marketed.
- There is no viable U.S. prescriber or payer demand for substitution against an unavailable originator.
- Clinical development would be difficult without a continuing commercial reference-product franchise.
- PML and serious infection concerns would make risk-benefit positioning problematic.
- The psoriasis market has shifted to newer biologic classes with stronger commercial support.
The relevant distinction is that Raptiva did not lose its market to a biosimilar. It lost its market because its safety profile became unacceptable relative to available alternatives.
What was the FDA regulatory status of Raptiva?
Raptiva is discontinued and not an active FDA product. The FDA’s principal regulatory actions were safety communications, labeling changes, and the eventual market withdrawal.
The central FDA concerns were:
- PML;
- serious infections;
- malignancies;
- thrombocytopenia;
- hemolytic anemia;
- immune-mediated complications;
- psoriasis rebound after treatment cessation.
The 2009 withdrawal eliminated the need for a conventional post-expiry launch analysis. Regulatory risk, rather than intellectual-property expiry, determined the product’s commercial endpoint.
What litigation and settlement agreements affected Raptiva?
There was no major patent-litigation or generic-settlement story comparable to those surrounding leading small-molecule medicines. Raptiva’s principal legal and commercial exposure was associated with product safety and withdrawal-related issues rather than market-entry litigation.
The absence of a major Paragraph IV settlement is commercially important. It means that generic competition, authorized-generic strategy, and patent settlement timing did not determine the product’s financial trajectory.
How strong was the Raptiva patent estate?
Raptiva’s patent estate was technically meaningful but commercially weak after withdrawal.
Technical strength
The estate likely covered specialized antibody constructs, target binding, production, and therapeutic use. Such rights can be difficult to design around when they cover the core antibody architecture or a defined epitope.
Commercial strength
Commercial strength fell sharply after the PML cases. Patent rights cannot preserve value when:
- the reference product is withdrawn;
- prescribers avoid the mechanism;
- regulators identify a potentially fatal safety risk;
- competing treatments offer safer or more flexible alternatives.
The effective life of the asset was therefore shorter than its potential legal life.
What generic launch scenarios existed for Raptiva?
There were no realistic post-withdrawal generic launch scenarios.
| Scenario |
Probability assessment |
Commercial rationale |
| Conventional generic launch |
Not applicable |
Raptiva was a biologic |
| Biosimilar launch before withdrawal |
Low |
Early U.S. biosimilar pathway was not operational |
| Biosimilar launch after withdrawal |
Very low |
No active reference-product market |
| Authorized biologic relaunch |
Very low |
Safety concerns affected the product itself |
| New indication for efalizumab |
Very low |
Risk-benefit profile remained unfavorable |
| Patent-driven delayed entry |
Not material |
Withdrawal, not patent expiry, controlled the market |
A follow-on developer would need to establish that a new version had an acceptable benefit-risk profile. That is a more difficult proposition than demonstrating similarity to a commercially successful reference biologic.
What licensing and corporate transactions involved Raptiva?
Genentech developed and commercialized Raptiva in the United States. Roche’s acquisition of Genentech in 2009 occurred during the period of Raptiva’s withdrawal, but the product was not a strategic growth asset in the combined company.
Raptiva did not produce a significant licensing ecosystem after discontinuation. Its commercial history was tied to Genentech’s internal development and marketing infrastructure rather than to a durable co-commercialization network.
What geographic markets did Raptiva cover?
Raptiva reached the United States and European markets before its withdrawal. European regulators coordinated suspension and withdrawal actions after the PML reports. The product’s geographic footprint contracted rapidly because the safety problem was not confined to a single national market.
The withdrawal reduced the asset’s geographic value in three ways:
- It removed U.S. revenue, the most commercially important market.
- It disrupted European availability.
- It eliminated the possibility of using international sales to offset U.S. regulatory damage.
What manufacturing and intellectual-property barriers remain?
Efalizumab manufacturing would require mammalian-cell expression, purification, viral clearance, characterization, sterility controls, and control of product quality attributes such as glycosylation and aggregation.
Those technical requirements would create ordinary biologic manufacturing barriers. They would not, however, compensate for the product’s commercial liabilities. A developer would need to solve the clinical and regulatory concerns surrounding the mechanism before manufacturing scale became relevant.
Key Takeaways
- Raptiva was efalizumab, a Genentech anti-CD11a biologic for chronic moderate-to-severe plaque psoriasis.
- The FDA approved it in October 2003 and the product was withdrawn in 2009.
- PML and serious infections, rather than patent expiry or generic competition, ended the franchise.
- Raptiva did not achieve the scale of leading psoriasis biologics and had limited multi-indication value.
- No meaningful Paragraph IV challenge or biosimilar launch determined its market exit.
- The product has no active commercial market, no current FDA exclusivity, and no practical generic-entry opportunity.
- Its patent estate may have retained technical rights after withdrawal, but those rights had little residual economic value.
- Raptiva’s financial trajectory illustrates how a serious safety signal can terminate a biologic franchise before intellectual-property expiry.
FAQs About Raptiva and Efalizumab
Is Raptiva still available in the United States?
No. Genentech voluntarily withdrew Raptiva from the U.S. market in 2009 after reports of PML and other serious adverse events.
Did Raptiva become a generic drug?
No. Raptiva was a biologic, not a conventional small-molecule drug. It was withdrawn before a meaningful biosimilar market developed.
What caused Raptiva sales to collapse?
The principal cause was the emergence of PML cases and the resulting unfavorable benefit-risk assessment. Competition from TNF inhibitors also limited growth before the withdrawal.
Could efalizumab return as a psoriasis treatment?
A commercial return is highly unlikely. Any relaunch would need to overcome the underlying PML and serious infection concerns, not merely resolve a manufacturing or patent issue.
Was Raptiva a blockbuster biologic?
No. It generated commercial revenue but did not become a major blockbuster franchise comparable with leading products such as Humira, Enbrel, Remicade, or Stelara.
References
- U.S. Food and Drug Administration. (2008). Raptiva prescribing information. FDA.
- U.S. Food and Drug Administration. (2009). FDA and Genentech notify patients and health care professionals of updated safety information for Raptiva. FDA.
- European Medicines Agency. (2009). European Medicines Agency recommends suspension of the marketing authorisation for Raptiva. EMA.
- Genentech, Inc. (2009). Annual report for the year ended December 31, 2008. Genentech.
- Roche Holding Ltd. (2010). Annual report 2009. Roche.
